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Although it is known that many stimuli can activate mitogen-
activated protein kinases (MAPKs) and phosphatidylinositol 3-
kinases (PI3K) in human neutrophils, little is known concerning
either the mechanisms or function of this activation. We have
utilized a selective inhibitor of MAPK kinase (MEK), PD098059,
and two inhibitors of PI3K, wortmannin and LY294002, to
investigate the roles of these kinases in the regulation of
neutrophil effector functions. Granulocyte}macrophage colony-
stimulating factor, platelet-activating factor (PAF) and N-for-
mylmethionyl-leucyl-phenylalanine are capable of activating
both p44ERK" and p42ERK# MAPKs and phosphotyrosine-asso-
ciated PI3K in human neutrophils. The activation of extracellular
INTRODUCTION
The regulation of neutrophil function through the interaction
with chemoattractants and cytokines is a critical aspect of host
defence against microbial infection. Furthermore, neutrophils
are implicated in the pathogenesis of a variety of inflammatory
diseases associated with tissue damage [1–3]. Neutrophils express
a wide range of receptors and become rapidly activated in
response to a diverse array of stimuli. These receptors include
tyrosine kinase-associated receptors such as granulocyte}macro-
phage colony-stimulating factor (GM-CSF) [4], seven-mem-
brane-spanning receptors such as N-formylmethionyl-leucyl-
phenylalanine (fMLP), platelet-activating factor (PAF), [5] and
receptors reacting with immune complexes, for example Fc [6].
After interaction of the ligand with the receptor, neutrophils
engage in migration, phagocytosis, antibody-dependent cell-
mediated cytotoxicity, granule release and production of super-
oxide [7,8]. Interestingly, optimal activation of neutrophils occurs
only in a ‘primed’ state induced by a prior stimulus [8]. For
example, pretreatment of neutrophils with GM-CSF primes the
NADPH oxidase for a subsequent challenge with fMLP without
directly activating the oxidase itself. However, the mechanisms
by which these factors activate or prime mature neutrophils
remain to be fully defined.
Tyrosine phosphorylation is thought to be crucial to the
regulation of neutrophil effector functions [9,10]. Although the
identities of many of the tyrosine-phosphorylated substrates
Abbreviations used: cPLA2, cytosolic PLA2 ; ERK, extracellular signal-related protein kinase ; fMLP, N-formylmethionyl-leucyl-phenylalanine; GM-CSF,
granulocyte/macrophage colony-stimulating factor ; GST, glutathione S-transferase ; MAPK, mitogen-activated protein kinase ; MEK, MAPK kinase ;
PAF, platelet-activating factor ; PI3K, phosphatidylinositol 3-kinase ; PLA2, phospholipase A2; PMN, polymorphonuclear cell ; RBD, Ras-
binding domain; STZ, serum-treated zymosan; TNF, tumour necrosis factor.
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signal-related protein kinases (ERKs) is correlated with the
activation of p21ras by both tyrosine kinase and G-protein-
coupled receptors as measured by a novel assay for GTP loading.
Wortmannin and LY294002 inhibit, to various degrees, super-
oxide generation, neutrophil migration and PAF release. In-
cubation with PD098059, however, inhibits only the PAF release
stimulated by serum-treated zymosan. This demonstrates that,
while neither MEK nor ERK kinases are involved in the acti-
vation of respiratory burst or neutrophil migration, inhibition
of PAF release suggests a potential role in the activation of
cytosolic phospholipase A
#
. PI3K isoforms, however, seem to
have a much wider role in regulating neutrophil functioning.
present in stimulated neutrophils remain unknown, it has been
demonstrated that members of the mitogen-activated protein
kinase (MAPK) family can be phosphorylated in response to
fMLP, PAF and GM-CSF [9,11–16]. There are three distinct
groups of MAPK: extracellular signal-related protein kinases
(ERKs) activated by a large variety of agonists, stress-activated
protein kinases and p38 MAPK. The latter two groups seem to
be more specifically activated by environmental stress and pro-
inflammatory cytokines. There is now considerable evidence
supporting a role for these evolutionary conserved protein kinases
in cellular growth and differentiation, although little is known of
the function of these kinases in haemopoietic systems.
Evidence pointing to the existence of additional neutrophil
signalling pathways has been obtained. One such pathway
concerns the lipid kinase phosphatidylinositol 3-kinase (PI3K),
which generates the putative signalling molecule inositol 3,4,5-
trisphosphate [17]. The use of the inhibitor wortmannin has
demonstrated that PI3K has a critical role in several neutrophil
effector functions including respiratory burst [18–20] and
assembly of the neutrophil actin cytoskeleton [21]. Neutrophils
contain two classes of PI3K: the classical p85}p110 heterodimer
[22,23] and a novel G-protein bc subunit-regulated PI3K [23].
The regulation of these two classes of PI3K by cytokines
and chemoattractants in human neutrophils remains to be
elucidated.
Several reports have suggested a role for the MAP}ERK
kinases in a variety of neutrophil functions [10,11,13,16]. The
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aim of the present study was to analyse the mechanisms of
activation and function of both p44ERK"}p42ERK# kinases and
PI3K in human neutrophils. Activation of ERKs by both tyrosine
kinase-linked and G-protein-coupled receptors is correlated with
activation of p21ras. Furthermore, all stimuli are capable of
activating phosphotyrosine-associated PI3K isoforms. Recently
a specific inhibitor of the MAP}ERK kinase activator MAPK
kinase (MEK) has become available (PD098059) [24,25]. Utiliz-
ing PD098059 and the PI3K inhibitorswortmannin or LY294002,
we have investigated the potential role of these two signalling
pathways in neutrophil function and priming. Results dem-
onstrate that the activation of PI3K seems to be critical for
superoxide generation, neutrophil chemokinesis and PAF release
mediated by serum-treated zymosan (STZ). Inhibition of cell
migration is apparent only for reagents activating granulocyte
chemokinesis rather than chemotaxis. The activation of MEK or
p44ERK"}p42ERK#, however, is only necessary for the STZ-induced
PAF release. Interestingly, the inhibition of PAF release by
PD098059, a cytosolic phospholipase A
#
(cPLA
#
)-mediated pro-
cess, suggests a possible role for ERK kinases in the activation of
cPLA
#
.
MATERIALS AND METHODS
Reagents
PAF (1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine),
fMLP and l-a-phosphatidylinositol were purchased from Sigma
(St. Louis, MO, U.S.A.). Human serum albumin was from the
Central Laboratory of the Netherlands Red Cross Blood Trans-
fusion Service (Amsterdam, The Netherlands). Recombinant
human GM-CSF (2.5¬10) i.u.}mg) was from Genzyme (Boston,
MA, U.S.A.). Percoll was obtained from Pharmacia (Uppsala,
Sweden). Polyclonal ERK2 antisera was a gift from Professor
J. L. Bos (Utrecht, The Netherlands) ; ERK-1 (C-16) and ERK-2
(C-14) polyclonal antisera were from Santa Cruz Biotechnology
(Santa Cruz, CA, U.S.A.). The anti-phosphotyrosine monoclonal
antibody (4G10) and anti-p85 polyclonal sera were obtained
from UBI (Lake Placid, NY, U.S.A.). Wortmannin and
LY294002 were purchased from BioMol (Plymouth Meeting,
PA, U.S.A.) and PD098059 was a gift from Dr. Dudley and Dr.
Saltiel (Parke-Davis Pharmaceuticals, Ann Arbor, MI, U.S.A.).
Isolation of human polymorphonuclear cells (PMNs)
Blood was obtained from healthy volunteers from the Red
Cross Blood Bank (Utrecht, The Netherlands). Mixed granulo-
cytes were isolated from the buffy coat of 500 ml of blood treated
with 0.4% trisodium citrate, pH 7.4, to prevent coagulation, as
previously described [26]. Mononuclear cells were removed by
centrifugation over isotonic Percoll (1.078 g}ml). After lysis of
the erythrocytes in isotonic ice-cold NH
%
Cl solution, the granu-
locytes were washed and resuspended in incubation buffer
[20 mM Hepes}132 mM NaCl}6 mM KCl}1 mM MgSO
%
}
1.2 mMKH
#
PO
%
, supplementedwith 5 mMglucose, 1 mMCaCl
#
and 0.5% (v}v) human serum albumin]. Granulocytes were
incubated for 30 min at 37 °C before stimulation.
ERK2 phosphorylation
PMNs were isolated as described above and incubated at 37 °C
for 30 min in incubation buffer. After stimulation, cells were
washed twice in ice-cold PBS and immediately lysed in sample
buffer essentially as described previously [27]. After being heated
for 5 min at 95 °C, total cell lysates were analysed on SDS}10%
(w}v) polyacrylamide gels. Proteins were transferred to Immo-
bilon-P and incubated with polyclonal ERK antiserum. Detec-
tion was by enhanced chemiluminescence (Amersham, Little
Chalfont, Bucks., U.K.).
MAPK activity
PMNs were isolated as described above and incubated at 37 °C
for 30 min. After stimulation, cells were washed twice in ice-cold
PBS and lysed in 50 mM Tris}HCl (pH 7.5)}100 mM NaCl}
50 mM NaF}5 mM EDTA}40 mM b-glycerophosphate}1 mM
Na
$
VO
%
}1% (v}v) Triton X-100}10 lg}ml aprotinin}10 lg}ml
leupeptin}1 mM PMSF. Lysates were precleared for 30 min at
4 °C with Protein A–Sepharose and MAPK was immunopre-
cipitated with 1 lg of ERK-1}ERK-2 polyclonal antiserum for
1 h at 4 °C on a rotating wheel. Protein A–Sepharose was then
added for a further 1 h at 4 °C. After being washed twice with
lysis buffer, samples were washed twice with kinase buffer without
ATP. Precipitates were then incubated in 25 ll of kinase buffer
[30 mM Tris}HCl (pH 8.0)}20 mM MgCl
#
}2 mM MnCl
#
}10 lM
rATP], containing 10 lg of myelin basic protein and 0.3 lCi of
[c-$#P]ATP, for 20 min at 30 °C. The reaction was stopped by the
addition of 5¬Laemmli sample buffer. Samples were separated
by SDS}PAGE [15% (w}v) gel]. Myelin basic protein
phosphorylation was detected by autoradiography.
p21ras activation assay utilizing Raf1 Ras-binding domain (RBD)
A fusion protein of glutathione S-transferase (GST) and RBD
(residues 51–131 of Raf1) was constructed and isolated as
described previously [28]. The desired amount of crude GST–
RBD was incubated with glutathione–agarose beads at 4 °C for
1 h. The beads were isolated by centrifugation and washed five
times with lysis buffer [50 mM Tris}HCl (pH 7.4)}150 mM
NaCl}1% Nonidet P-40}10% (v}v) glycerol}0.1 lM apro-
tinin}1 lM leupeptin}1 mM PMSF). PMNs (10( cells) were
lysed in 1 ml of lysis buffer at 4 °C and centrifuged to remove
nuclei. Precoupled GST–RBD beads were added and the lysates
were incubated for 30 min at 4 °C. Beads were pelleted by cen-
trifugation and washed three times with lysis buffer before being
resuspended in Laemmli sample buffer. Protein samples were
separated by SDS}PAGE [15% (w}v) gel] and transferred to a
PVDF membrane. Western blots were probed with the anti-Ras
monoclonal antibodyY13-259 for 16 h at 4 °C, followedby rabbit
anti-rat antiserum (2 h at 4 °C) and horseradish peroxidase-
coupled goat anti-rat antiserum (Santa Cruz) (1.5 h at 4 °C).
Blots were developed by enhanced chemiluminescence (New
England Nuclear, Boston, MA, U.S.A.).
PI3K activity
PMNs were treated as described above. After stimulation, reac-
tions were stopped by adding 2 vol. of ice-cold incubation buffer
containing 2 mM Na
$
VO
%
. Subsequently the PMNs were pelleted
by centrifugation at 4 °C before being resuspended for 30 min
at 4 °C in lysis buffer [1% Triton X-100}20 mM Tris}HCl
(pH 8.0)}100 mMNaCl}10 mMNa
%
P
#
O
(
}2 mMEDTA}50 mM
NaF}10% (v}v) glycerol}10 lg}ml aprotinin}10 lg}ml leupep-
tin}10 lg}ml soybean tryptase inhibitor}1 mM PMSF}1 mM
Na
$
VO
%
]. Lysates were incubated for 1 h at 4 °C on a rotating
wheel with 1 lg of anti-phosphotyrosine monoclonal antibody
4G10 before the addition of Protein A–Sepharose for a further
1 h. Samples were washed three times with lysis buffer and twice
with 10 mM Tris}HCl, pH 7.4, containing 1 mM Na
$
VO
%
. PI3K
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activity was measured by adding 100 lg of sonicated phospha-
tidylinositol and 20 lCi of [c-$#P]ATP in the presence of 200 lM
adenosine (to inhibit phosphatidylinositol 4-kinase activity),
30 mM MgCl
#
and 35 lM ATP in a total volume of 60 ll.
Reactions were performed for 20 min at room temperature and
stopped by the addition of 100 ll of 1 M HCl and 200 ll of
chloroform}methanol (1 :1, v}v). After centrifugation and re-
moval of the upper layer, 80 ll of methanol}HCl (1:1) was
added. After further centrifugation, lipids were separated on TLC
plates (Merck) with a solvent system of chloroform}methanol}
NH
%
OH (45:35:10, by vol.). TLC plates were exposed to X-ray
film at ®80 °C. Immunoprecipitation with polyclonal anti-p85
antibody was used as positive control for PI3K activity.
Migration assay
PMN migration was measured with a modification of the method
of Boyden [29], by using a 48-well microchemotaxis chamber
(Neuroprobe, Cabin John, MD, U.S.A.). Chemotaxins or in-
cubation buffer (30 ll) were added to the lower compartments.
Two filters were placed between the lower and upper compart-
ments. The lower filter (Millipore, Bedford, MA, U.S.A.) had a
pore width of 0.45 lm, whereas the upper filter (cellulose nitrate)
had a pore width of 8 lm (thickness 150 lm; Sartorius, Go$ t-
tingen, Germany). Before use the filters were soaked in incubation
buffer. PMNs were placed in the upper compartment (25 ll, of
2¬10' cells}ml). The chambers were subsequently incubated for
1.5 h at 37 °C. The upper filters were removed, fixed in butanol}
ethanol (20:80, v}v) for 10 min and stained with Weigert solution
[1% (v}v) haematoxylin in ethanol}70 mM acidic FeCl
$
; 1 :1
(v}v)]. The filters were dehydrated with ethanol, made trans-
parent with xylene and fixed upside down. All migratory re-
sponses were quantified with an image analysis system (Quan-
timet 570C; Leica Cambridge) with Quantimet 570 Control
Software (QUIC version 2.02) and custom software. An auto-
mated microscope (Leitz DMRXE; Leica, Weitzlar, Germany)
was used to step through the filters in the z direction with 17
intervals of 10 lm. PMNs were counted at each level and the
total migration to each level was calculated. The results are
expressed as migratory index (lm per cell), which is calculated by
the cumulative migration of all intervals (in lm) divided by the
total number of cells. In this index the cells at level 0 lm were not
included. The mean of four randomly chosen points on each
filter spot was calculated.
Measurement of PAF release
After incubation with or without GM-CSF (100 pM) for 30 min,
STZ (0.5 mg}ml) was added to the PMNs (10' cells}ml) for a
subsequent incubation of 30 min at 37 °C with vigorous shaking.
Cells and zymosan particles were then removed by centrifugation
(at 4 °C and 200 g for 15 min) and the supernatants were collected
and stored at ®80 °C. PAF was measured in these samples with
a competitive radioimmunoassay (New England Nuclear).
Measurement of superoxide production
Superoxide was measured by cytochrome c reduction by the
method of Pick and Mizel [30], with modifications. Briefly,
PMNs (4¬10' cells}ml) were preincubated for 5 min at 37 °C in
incubation buffer. Inhibitors and}or cytokines were then added
for the indiated periods; the cells (200 ll) were transferred to a
microtitre plate in a thermostat-controlled microtitre plate reader
(340 ATTC; SLT LabInstruments, Salzburg, Austria), mixed
with cytochrome c (75 lM) and the incubation was continued
for 5 min. The plates were shaken every 3 s. The cells were then
stimulated with fMLP (1 lM) and cytochrome c reduction was
measured every 12 s as an increase in A
&&!
(e
&&!
¯ 21¬10$
M−"[cm−"). Results are expressed as the maximal rate of super-
oxide production produced by 10( cells}min.
RESULTS
Activation of MAPKs by PMN stimulants
We analysed the ability of various reagents to induce both the
phosphorylation and activity of the MAPKs p44ERK" and
p42ERK#. Phosphorylation of MAPK on threonine and tyrosine
residues results in a mobility shift in SDS}PAGE. As shown in
Figure 1(A), ERK2 was phosphorylated in extracts of cells
stimulated by both cytokines and chemoattractants. Interest-
ingly, all stimulants provided different activation profiles. The
phosphorylation was strongest and more transient after stimu-
lation by ligands of serpentine receptors fMLP and PAF, whereas
stimulation with GM-CSF, whose action is mediated by a single
transmembrane receptor, was of much longer duration but less
potent. The addition of tumour necrosis factor a (TNF-a) to
PMNs resulted in a very weak and extremely transient activation
of ERK2 phosphorylation. The very weak activation of p42ERK#
by TNF-a is in agreement with Waterman and Sha’afi [14], who
found no activation of p44ERK" or p42ERK# in human neutrophils.
To analyse the activity of ERK kinases in response to these
stimuli we performed immune-complex kinase assays utilizing
immunoprecipitating antibodies to both p44ERK" and p42ERK#.
The results shown in Figure 1(B) corroborate the phosphoryl-
ation results described above. Taken together, they demonstrate
that the MAPKs p44ERK" and p42ERK# can be activated by both
cytokines and chemoattractants in human neutrophils and that
their regulation by fMLP and PAF is distinct from that by GM-
CSF.
Activation of p21ras is correlated with activation of ERK by GM-
CSF, PAF and fMLP
Although the activation of ERKs by tyrosine kinase-linked
receptors is p21ras-dependent, this correlation has not been widely
established for other receptor families such as G-protein-coupled
receptors. Although fMLP has been reported to activate GTP-
loading of p21ras [31], activation of p21ras was not observed for
PAF [32]. We have utilized a Raf1-RBD as an activation-specific
probe for p21ras GTP-loading after stimulation of neutrophils by
GM-CSF, TNF-a, fMLP and PAF. This technique is based on
the principle that Raf1 interacts only with GTP-bound p21ras.
Thus a GST fusion protein containing the minimal RBD of Raf1
(residues 51–131) is used to ‘pull down’ GTP-bound p21ras [28].
Although not quantitative, this method provides results on the
ability and kinetics of activation. PMNs were stimulated and
p21ras was precipitated with GST–RBD bound to glutathione–
agarose beads and identified by Western blotting with a mono-
clonal antibody against p21ras. As shown in Figure 2, TNF-a,
which failed to activate p44ERK" or p42ERK#, also failed to induce
p21ras activation, whereas GM-CSF, which produced a slow but
sustained activation of ERKs, also resulted in an identical
activation profile for p21ras. Furthermore, activation of the G-
protein-coupled receptors for PAF and fMLP resulted in a very
rapid and short-lived p21ras activation perfectly correlated with
their activation of ERKs. Thus it seems that all neutrophil
stimuli that activate ERKs also activate p21ras with the same
kinetics, suggesting that p21ras activation is necessary for signal
propagation to ERKs.
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Figure 1 Cytokines and chemoattractants stimulate ERK phosphorylation and activity
(A) Isolated neutrophils were incubated for 30 min at 37 °C in incubation buffer before stimulation. GM-CSF (100 pM), PAF (1 lM), fMLP (1 lM) and TNF-a (100 i.u./ml) were incubated for
the times indicated. After stimulation, cells were immediately lysed in Laemmli sample buffer and samples were analysed by ERK2 Western blotting as described in the Materials and methods
section. (B) Cells were stimulated for the times indicated. After stimulation, samples were lysed and immunoprecipitated with a mixture of p44ERK1 and p42ERK2 antibodies. Kinase activity was analysed
as described in the Materials and methods section.
Figure 2 GM-CSF, fMLP and PAF stimulate p21ras activation in neutrophils
PMNs were stimulated as indicated (TNF-a, 100 i.u./ml ; GM-CSF, 100 pM; PAF, 1 lM; fMLP,
1 lM) before lysis and incubation with GST–RBD to bind GTP-bound p21ras as described in
the Materials and methods section. Samples were analysed by SDS/PAGE and immunoblotting
with a monoclonal antibody against p21ras. The position of immunoprecipitated p21ras is marked
by an arrowhead.
PD098059 inhibits activation of PMN p44ERK1/p42ERK2
To analyse the role of ERK activation in neutrophil effector
functions we utilized the recently identified inhibitor PD098059
[24,25]. This compound has been described to specifically inhibit
the upstream MAPK kinases (MEK1 and MEK2) in several cell
lines. To determine whether PD098059 could inhibit ERK
phosphorylation and activation by cytokines and chemoattrac-
tants in human PMNs we peformed both mobility-shift and
kinase assays on cells pretreated for 20 min with or without
PD098059. As shown in Figure 3(A), increasing concentrations
of PD098059 resulted in a decrease in ERK2 phosphorylation
with a half-maximal inhibition of approx. 10 lM. To analyse the
effect on both p44ERK" and p42ERK# we utilized immune-complex
kinase assays. The results shown in Figure 3(B) demonstrate a
similar pattern for kinase activity to that observed for mobility-
shift analysis. Thus it seems that all three stimulants, fMLP, PAF
and GM-CSF, require MEK1 or MEK2 for activation of ERK
isoforms in human PMNs. Furthermore, PD098059 at concen-
trations of 10–50 lM can be utilized to block MEK}ERK
activity completely in human neutrophils.
GM-CSF, PAF and fMLP induce phosphotyrosine-associated PI3K
activity in PMNs
The mechanism of activation of PI3K in human neutrophils has
not been thoroughly investigated. To determine whether cyto-
kines and chemoattractants activate the classical p85-linked
PI3K we measured the phosphatidylinositol-phosphorylating
activity present in phosphotyrosine immunoprecipitates from
stimulated neutrophils. After immunoprecipitation and kinase
assay, phosphorylated lipids were separated by TLC (as described
in the Materials and methods section). As shown in Figure 4(A),
GM-CSF induces a rapid induction of PI3K activity. Interest-
ingly, a similar rapid induction was observed for the serpentine
receptor agonists fMLP and PAF (Figure 4B). This clearly
demonstrates that these G-protein-coupled receptors are also
capable of activating phosphotyrosine-associated PI3K activity,
in contrast with other reports [22]. To inhibit PI3K activity we
utilized both the fungal metabolite wortmannin and the synthetic
inhibitor LY294002 [19,33]. Pretreatment of cells with 30 nM
wortmannin for 20 min was sufficient to inhibit more than
90% of phosphotyrosine-associated PI3K activity (Figure 4B).
This was true of all stimulants (GM-CSF, fMLP and PAF)
tested. These concentrations of wortmannin had no effect on
ERK activation in PMNs (results not shown). Importantly
this demonstrates that GM-CSF as well as the serpentine re-
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Figure 3 PD098059 inhibits ERK phosphorylation and activation by both cytokines and chemoattractants
(A) Isolated neutrophils were incubated with DMSO or increasing concentrations of PD098059 for 20 min and then stimulated as indicated. Phosphorylation of p42ERK2 was monitored by SDS/PAGE
and Western blotting as described in the Materials and methods section. (B) Cells were treated as described above and MAPKs were immunoprecipitated with a mixture of p44ERK1 and p42ERK2
antibodies before being analysed in kinase assays as described above.
Figure 4 Cytokines and chemoattractants activate a phosphotyrosine-
associated PI3K activity that is inhibited by wortmannin
(A) Isolated neutrophils were stimulated with GM-CSF (100 pM) for the times indicated. After
lysis, phosphotyrosine-associated PI3K activity was immunoprecipitated with 4G10 monoclonal
antibody and lipid kinase assays in vitro were performed as described in the Materials and
methods section. The position of phosphorylated phosphatidylinositol is marked by PIP. (B)
Neutrophils were preincubated with DMSO alone or with 30 or 100 nM wortmannin (Wort)
for 15 min. Samples were harvested and PI3K assays were performed as described above.
Ori, origin.
ceptor agonists fMLP and PAF are capable of activating
phosphotyrosine-associated PI3K (p85}p110) activity.
Effect of PI3K or MEK inhibition on respiratory burst
Stimulation of neutrophils with the chemotactic peptide fMLP
induces the rapid formation of microbicidal oxidants, a process
dependent on prior priming of cells with cytokines, chemo-
attractants or lipopolysaccharide [34–36]. Activation is a result
of the rapid assembly of the NADPH oxidase system, a process
that in io is dependent on the phosphorylation of oxidase
components, e.g. p47phox. Previous reports have suggested roles
for PI3K in this process [18,20,33,37], whereas a role for p44ERK"
and p42ERK# MAPKs has also been proposed, although in-
directly [38–40]. We therefore analysed the effect of preincubation
of human neutrophils with various concentrations of PD098059
or wortmannin}LY294002 on fMLP-induced respiratory burst,
continuously measured by cytochrome c reduction (as described
in the Materials and methods section). Neutrophils were then
pretreated with the priming agents GM-CSF, PAF and TNF-a.
As shown in Figure 5(A), treatment of cells with different
concentrations of PD098059 for 20 min before stimulation had
no effect on fMLP-induced respiratory burst. Even at 50 lM
PD098059, a concentration that we have shown to inhibit all
ERK activity (Figure 2), there was no effect on superoxide
production. We have analysed the effect of these inhibitors on
cytokine-primed respiratory burst and thus it seems that ac-
tivation of MEK}ERK kinases is not required for either the
activation or the priming of the NADPH oxidase system, in
contrast with other suggestions [38–40]. Other reports [20,33,37]
have demonstrated that inhibition of PI3K results in a decrease
in fMLP-induced respiratory burst. As shown in Figure 5(B),
increasing concentrations of wortmannin or LY294002 do indeed
inhibit superoxide production. The addition of 30–100 nM
wortmannin or 10 lM LY294002 to GM-CSF-primed neutro-
phils results in an almost complete inhibition of O
#
− production,
as measured by cytochrome c reduction. This correlates well with
the inhibition of PI3K as measured by immune-complex kinase
assays (Figure 4B). Interestingly, although wortmannin inhibits
the PAF-primed respiratory burst, the concentration of wort-
mannin required is higher than that needed to abolish PI3K
activity in immune-complex kinase assays from PAF- or fMLP-
stimulated cells (Figure 4B). This can be explained by the fact
that the kinase assays measure only phosphotyrosine-associated
PI3K activity, e.g. p85–p110a. It has been reported that neutro-
phils also express p110c, a G-protein-activated PI3K isoform
[23]. The p110c PI3K isoform is inhibited by much higher
concentrations of wortmannin in intact cells (IC
&!
200 nM) than
p110a [23]. This suggests that for the PAF- and TNF-a-primed
respiratory bursts different isoforms of PI3K are utilized in the
activation of the NADPH oxidase system from that for GM-
CSF.
Effect of wortmannin and PD098059 on PMN migration
The influx of inflammatory cells into tissues involves processes
such as cell rolling, attachment to endothelial cells, spreading,
trans-endothelial diapedesis and directed migration to the inflam-
matory site or chemotaxis. To determine whether MEK-ERK or
PI3K might have a role in neutrophil migration we utilized a
modification of the method described by Boyden ([29] ; see the
Materials and methods section) with a 48-well microchemotaxis
chamber. Cytokine or chemoattractant was placed in the
lower chamber and migratory activity was measured. As can be
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Figure 5 Effect of inhibitors of PI3K and MEK on fMLP-induced neutrophil respiratory burst
Neutrophils were preincubated with DMSO, increasing amounts of PD098059 for 20 min (A) or wortmannin for 15 min (B), before the addition of priming agents. GM-CSF (100 pM; 30 min), PAF
(1 lM; 2 min) or TNF-a (100 i.u./ml ; 30 min) was added before stimulation with fMLP. Superoxide production was monitored continuously by measurement of cytochrome c reduction as described
in the Materials and methods section. Results are represented as percentages of burst relative to control cells and are means³S.E.M. (n ¯ 4). Control rates : GM-CSF, 19.2³1.5 nmol of O2−/min
per 107 cells ; PAF, 23.6³1.5 nmol/min per 107 cells ; TNF-a, 16.5³1.5 nmol/min per 107 cells.
seen in Figure 6(A), all three stimuli provoked an apparent
migratory activity to different degrees, fMLP being the most
potent and GM-CSF the weakest.
To determine the effect of inhibiting p44ERK" and p42ERK#
MAPKs on neutrophil migration we preincubated PMNs with
various concentrations of PD098059 before performing Boyden-
chamber migration assays (Figure 6B). It is clearly seen that even
at concentrations of 50 lM, enough to inhibit all ERK activity
totally, cell migration is more than 90% of control values for all
stimuli measured. This demonstrates that although it has been
previously postulated that activation of MAPKs might have a
role in granulocyte migration [10], there is no apparent role for
either p44ERK" or p42ERK#.
We next analysed the potential role of PI3K in neutrophil
migratory responses. As is seen in Figure 6(C), there is a clear
distinction between the effect of wortmannin on unstimulated or
GM-CSF-stimulated cells compared with fMLP or PAF. Where-
as 100 nM wortmannin inhibits migration by 50% for buffer or
GM-CSF, for PAF and fMLP even 200 nM results in less than
10% inhibition. We have recently reported that for migration of
eosinophilic granulocytes, the increased locomotion induced by
GM-CSF is due to enhanced chemokinesis of cells rather than
chemotaxis [41]. In contrast, PAF-induced migration is mainly
gradient-dependent and is thus chemotaxis. As shown in Figure
6(D), the same distinction can apparently be made for neutro-
phils. Whereas PAF acted as a true chemoattractant, GM-CSF
stimulated chemokinesis rather than chemotaxis, as measured by
its ability to stimulate migration if present in either the upper or
the lower chamber, e.g. non-gradient-directed. Thus for PMNs,
wortmannin seems to inhibit only those agonists responsible for
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Figure 6 Effect of PD098059 and wortmannin on neutrophil migration
(A) Migration of neutrophils was monitored in microchemotaxis Boyden chambers in response to buffer, GM-CSF (100 pM), PAF (10 nM) or fMLP (10 nM) as described in the Materials and methods
section. Cytokines or chemoattractants were placed in the lower compartment and cells were left to migrate for 1.5 h at 37 °C. Results are expressed as migratory index (lm per cell) and are
means³S.E.M. (n ¯ 4). Neutrophils were preincubated with DMSO, increasing amounts of PD098059 for 20 min (B) or wortmannin for 15 min (C), before analysis in microchemotaxis Boyden
chambers as described above. In (D), cells were stimulated with increasing concentrations of either PAF or GM-CSF in either the upper chamber (+) or the lower chamber (E). Results are
expressed as percentage migrations relative to control cells not preincubated with inhibitor (n ¯ 4).
Figure 7 PD098059 and wortmannin each inhibit STZ-stimulated PAF
release in human neutrophils
Isolated neutrophils were incubated for 20 min with PD098059 (A) or for 15 min with
wortmannin (B) and then additionally for 30 min with (_) or without (+) GM-CSF (100 pM).
STZ (0.5 mg/ml) was then added for a further 30 min before supernatants were collected and
concentrations of PAF were measured by radioimmunoassay as described in the Materials and
methods section. Results are expressed as PAF release (ng of PAF per 106 cells) and are
means³S.E.M. (n ¯ 4).
increased granulocyte chemokinesis. This suggests that activation
of PI3K isoforms is critical for enhanced random movement of
cells rather than gradient-directed migration.
PD098059 and wortmannin both inhibit STZ-induced PAF release
Neutrophils are potently stimulated by opsonized particles such
as STZ coated with, for example, IgG and iC3b, resulting in the
activation of the respiratory burst and the production of lipid
mediators such as PAF and leukotriene-C
%
[42]. The process of
lipid release is up-regulated or primed by pretreatment of cells
with GM-CSF. Relatively little is understood about the mech-
anisms involved in this response, although a role for cPLA
#
has
been defined [43]. To determine whether the activation of MEK-
ERK or PI3K signal-transduction pathways might have a role in
this process we analysed the release of PAF from GM-CSF-
primed STZ-stimulated PMNs. Supernatants were collected from
stimulated cells and PAF (ng}10' cells) was analysed by com-
petitive radioimmunoassay. As can be seen in Figure 7(A), the
addition of increasing concentrations of PD098059 inhibits STZ-
stimulated PAF release with a profile that is well correlated with
the inhibition of ERK activity (Figure 2). Priming of PMNs by
pretreatment with GM-CSF (100 pM) before treatment with
STZ results in a much greater release of PAF, as has been
previously described (Figure 7A). PAF release induced in this
primed system is also inhibited by incubation with PD098059;
however, 50 lM PD098059 decreases this only to 50% of the
control value. Thus, whereas STZ seems to require functional
MEK for the generation of PAF, GM-CSF-primed cells are able
to short-circuit this requirement, presumably by the induction of
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other downstream protein kinases. A similar reponse was ob-
served for the effect of wortmannin on both primed and unprimed
STZ-mediated PAF release (Figure 7B). Unprimed PMNs were
very sensitive to wortmannin, with 50% inhibition occurring at
approx. 30 nM. The effect of inhibitor on GM-CSF-primed
PMNs was, however, much less marked, with 100 nM wort-
mannin resulting in only a 20% decrease in PAF release
compared with control values. This again suggests that cytokine-
mediated priming of neutrophils results in the activation of
distinct signalling pathways capable of enhancing or replacing
those utilized in the unprimed reponse.
DISCUSSION
In this paper we have analysed the activation of both p44ERK"}
p42ERK# MAPKs and phosphotyrosine-associated PI3K in hu-
man neutrophils. Furthermore, we have compared for the first
time the effects of inhibiting these two signal transduction
cascades on various aspects of neutrophil effector functioning. A
role for the p44ERK"}p42ERK# MAPKs in neutrophil functioning
has previously been proposed by several studies [10–14,44]. The
MEK inhibitor PD098059 has been recently utilized to confirm
a role for both p44ERK"}p42ERK# MAPKs in fibroblast cell
growth and differentiation [24,25], as well as in platelet
functioning [45]. By adding this synthetic inhibitor to human
neutrophils we have been able to determine the effect of blocking
MEK-ERK signalling on downstream effector functions.
Activation of p21ras involves the exchange of GDP for GTP
and the subsequent binding of various Ras-effector molecules
such as Raf1 and PI3K. We have utilized this observation to
analyse p21ras activation by its ability to bind to Raf1-RBD only
when bound to GTP [28]. We have demonstrated the activation
of p21ras by a variety of receptors in intact human neutrophils
(Figure 2). This is the first time that this technique has been
utilized in primary cells and provides a powerful method for
characterizing p21ras activation. Most interesting is the activation
kinetics observed with the various stimuli. Whereas TNF-a is
incapable of activating p21ras, GM-CSF stimulates a slow
activation of relatively long duration (more than 20 min). In
contrast, the G-protein-coupled receptor agonists PAF and
fMLP induce a very rapid (less than 10 s) and short-lived (less
than 5 min) p21ras activation. This activation is correlated with
the activation of p44ERK" and p42ERK# for all stimuli in neutro-
phils, suggesting either that p21ras must be bound to GTP to
maintainERK activation or that these signals are down-regulated
at the same time. It has recently been reported that fMLP
stimulates the tyrosine phosphorylation and subcellular redis-
tribution of p125 GAP, a p21ras GTP-activating protein [46],
providing a potential down-regulatory mechanism.
Activation of PI3K can be measured by using anti-phospho-
tyrosine immunoprecipitates and lipid kinase assays in itro. We
have clearly demonstrated that GM-CSF, PAF and fMLP all
stimulate phosphotyrosine-associated PI3K activity that is in-
hibited by low concentrations of wortmannin (Figures 4A and
4B). This is in direct contrast with a study by Vlahos and Matter
[22], who demonstrated fMLP-inducible PI3K activity in neutro-
phils but observed no PI3K activity in anti-phosphotyrosine
immunoprecipitates. Furthermore they observed no tyrosine
phosphorylation of p85. Although it is possible that p85 is not
tyrosine phosphorylated but associates with one ormore tyrosine-
phosphorylated proteins, it is difficult to reconcile the differences
between this study and our own, but differences in phospho-
tyrosine antibodies might be responsible.
The activation of respiratory burst is a metabolic event during
which phagocytes generate antimicrobicidal oxidants by the
reduction of oxygen to superoxide. Activation of this effector
response requires prior priming of the cells with cytokines,
chemoattractants or lipopolysaccharide. The NADPH oxidase
itself is a multicomponent enzyme whose components are dis-
tributed between cytosol and plasma membrane. After stimu-
lation of cells, cytosolic components migrate to the plasma
membrane, where they associate with cytochrome components to
generate the active oxidase [34–36]. Associated with oxidase
activation is the phosphorylation of the cytosolic component
p47phox [39,47,48]. Regions surrounding the Ser-345 and Ser-348
phosphorylation sites in p47phox contain the motif Pro-Xaa-Ser-
Pro, which is a consensus phosphorylation site for MAPKs
[49,50]. It has therefore been suggested that phosphorylation of
p47phox by MAPKs might also have a role in the translocation of
this oxidase component to the plasma membrane and activation
of the respiratory burst [39]. Our results on the effect of PD098059
on superoxide production demonstrate that this is not so (Figure
5A). The inhibition of p44ERK" and p42ERK# activation does not
affect fMLP-induced respiratory burst in cells primed with GM-
CSF,TNF-aor PAF.Clearly the activation of theERK signalling
pathway does not have a crucial role in any aspect of NADPH
oxidase activation. In contrast with the effect of PD098059, the
addition of wortmannin or LY294002 inhibited fMLP-induced
respiratory burst for all three priming stimuli (Figure 5B). It has
also been demonstrated that both wortmannin and LY294002
can inhibit fMLP-stimulated oxidant production [20,33,37].
These studies did not, however, investigate in detail the effect of
various priming agents on this response. In Figure 5(B) it is clear
that wortmannin inhibits fMLP-stimulated superoxide produc-
tion in GM-CSF-, PAF- and TNF-a-primed cells. Interestingly,
GM-CSF-primed cells are inhibited atmuch lower concentrations
of wortmannin than PAF-primed cells. It has previously been
described that human neutrophils contain both a tyrosine kinase-
linked PI3K, p110a, as well as a G-protein-linked PI3K, p110c
[23]. Interestingly, whereas p110a-mediated PtdIns(3,4,5)P
$
ac-
cumulation is inhibited by relatively small amounts of wort-
mannin in intact cells (IC
&!
! 50 nM), p110c requires much
higher concentrations (IC
&!
" 200 nM). This is correlated with
the differential effects of wortmannin described here (Figure 5B).
Whereas wortmannin inhibited GM-CSF-primed oxidant pro-
duction with an IC
&!
of less than 30 nM, the IC
&!
for PAF was
more than 100 nM. This suggests that whereas GM-CSF priming
might involve p110a, PAF priming probably also utilizes p110c.
It has previously been shown that TNF-a can prime the
neutrophil respiratory burst [38,51,52] and that this can be
inhibited by tyrosine kinase inhibitors. For TNF-a priming, the
IC
&!
of wortmannin inhibition was approx. 50 nM, suggesting a
role for p110a in io (Figure 5B). GM-CSF, PAF and TNF-a all
demonstrate distinct inhibition profiles, suggesting that different
receptors can potentially utilize different PI3K isoforms or
combinations of isoforms in the priming and activation of the
NADPH oxidase complex. Recently several protein kinase ac-
tivities present in human neutrophils have been shown to be
inhibited by wortmannin [53]. These same kinases have also been
shown to phosphorylate p47phox in itro ; furthermore, wort-
mannin has been shown to inhibit p47phox phosphorylation in
io [53]. These results suggest that a serine}threonine protein
kinase downstream of PI3K might be involved in the activation
of the NADPH oxidase. One such kinase could be protein kinase
B, whose activity is inhibited by antagonizing PI3K activation
[54,55]. We have shown that protein kinase B is indeed activated
in response to both cytokines (interleukin 5, GM-CSF and
interleukin 4) and chemoattractants (PAF, fMLP and C5a) in
human granulocytes (P. J. Coffer, R. C. Schweizer and L.
Koenderman, unpublished work). Recently it was demonstrated
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that the introduction of a constitutively active form of PI3K into
a monoblastic phagocyte line (GM-1) caused constitutive acti-
vation of protein kinase B and also phosphorylation of p47phox
[56].
Activation of phospholipase A
#
(PLA
#
) results in the pro-
duction of lyso-PAF, the precursor for the synthesis of PAF [57].
Incubation of neutrophils with opsonized particles results in the
activation of the respiratory burst as well as the release of PAF
[42]. We have found that preincubating neutrophils with
PD098059 completely inhibits STZ-stimulated PAF release
(Figure 7A). Furthermore PD098059 greatly decreases the GM-
CSF-primed STZ-stimulated PAF release (60% inhibition;
Figure 7A). Studies have demonstrated that cPLA
#
is inducibly
serine-phosphorylated and that it is a substrate for p42ERK# in
itro [58]. Furthermore, it has recently been shown that GM-CSF
promotes the phosphorylation and activation of cPLA
#
in human
neutrophils [15]. Our results suggest, although indirectly, that the
activation of MEK-ERK might indeed be a requirement for the
activation of cPLA
#
in human neutrophils. The fact that
PD098059 does not completely inhibit GM-CSF-primed STZ-
stimulated PAF release suggests that priming can somehow
override the requirement for MEK-ERK activation of cPLA
#
,
possibly by activation of a secondary signalling pathway. Indeed,
TNF-a does not activate p44ERK"}p42ERK# but does cause the
phosphorylation of cPLA
#
, demonstrating a mitogen-activated
protein kinase (MAPK)-independent pathway (Figure 1A) [14].
Furthermore, a recent study has demonstrated a role for p38
MAPK in the phosphorylation of cPLA
#
in platelets [59]. As
shown in Figure 7B, wortmannin also quite markedly inhibits the
release of PAF in unprimed cells. Thus it is probable that
different stimuli might activate different combinations of cPLA
#
-
phosphorylating}activating kinases.
The ability of leucocytes to move along a chemotactic gradient
is crucial to their accumulation at sites of injury or infection
(reviewed in [7]). To determine the effect of MEK-ERK inhibition
on neutrophil motility we utilized a microchemotaxis chamber
(Figure 6). The addition of PD098059 to cells before the assay
resulted in no change in the migratory behaviour of the cells in
response to buffer, GM-CSF, PAF or fMLP (Figure 6B). This
demonstrates that there is apparently no requirement for MEK-
ERK activation in the migratory movement of neutrophils, or in
the detection of chemotactic gradients. More interestingly, wort-
mannin inhibited neutrophil chemokinesis but not chemotaxis
(Figure 6C). Products of PI3K-induced phosphorylation of
membrane lipids, e.g. PtdIns(3,4,5)P
$
, have been suggested to
mediate cytoskeletal changes, especially in Rac-mediated mem-
brane ‘ruffling’ [21,60–62]. It has been demonstrated that PI3K
is necessary for the activation by platelet-derived growth factor
(PDGF) of Rac-mediated rearrangements of the actin cyto-
skeleton, possibly by regulating GTP loading on Rac [62–64]. It
is therefore tempting to speculate that the activation of Rac in
neutrophils by PI3K might be involved in GM-CSF-stimulated
cell chemokinesis in much the same way as PDGF causes ruffling
in fibroblasts [62,64]. However, it seems that this signalling
pathway is not required for chemotaxis. which cannot be
inhibited by high concentrations of wortmannin.
Taken together, our results demonstrate that, whereas the
activation of PI3K in human neutrophils seems to have an
important role in granulocyte effector functions, the MEK-ERK
signalling cascade is more restricted to processes such as active
lipid release. Another function of MEK-ERK stimulation is the
activation of gene transcription via the potentiation of tran-
scription factor transactivation, protein stability or increased
binding of DNA (reviewed in [65,66]). It could be that in
neutrophils p44ERK" and p42ERK# also have a role in gene
induction responsible, for example, for the up-regulation of
adhesion molecules such as Mac-1}LFA-1 or selectins, necessary
for neutrophil migration in io. Complex cross-talk between the
sigalling pathways described here will determine the eventual
outcome of agonist-induced downstream responses. The ac-
tivation of the p21ras–ERK signal transduction pathway thus
probably allows fine-tuning of the regulation of these downstream
effects in response to cellular activation.
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